Patients must fulfill all of the following inclusion criteria to be eligible for enrollment in this study:  Histologically confirmed locally advanced (T1N1-3M0 or T2-3N0-3M0) squamous cell carcinoma of the thoracic esophagus (per the 8th Edition of UICC-TNM Classification); No suspicious cervical lymph node metastasis on cervical contrast-enhanced CT; no systemic metastasis from radiological examination; Expected to be achievable to conduct R0 resection.  Patients must not enter this study if any of the following exclusion criteria is fulfilled:  Having malignant tumors other than esophageal carcinoma within 5 years prior to randomization; Combined with other inoperable condition; Previous serious allergy to chemotherapeutic agents (paclitaxel or cisplatin) or any monoclonal antibody; Combined with other conditions unsuitable for participation in this study as judged by investigators.  Other protocol defined Inclusion/exclusion criteria could apply.